DNA Repair in Cancer Therapy

Elsevier Science and Technology, October 2011, Pages: 330

Cancer therapeutics include an ever-increasing array of tools at the disposal of clinicians in their treatment of this disease. However, cancer is a tough opponent in this battle, and current treatments, which typically include radiotherapy, chemotherapy and surgery, are not often enough to rid the patient of his or her cancer. Cancer cells can become resistant to the treatments directed at them, and overcoming this drug resistance is an important research focus. Additionally, increasing discussion and research is centering on targeted and individualized therapy. While a number of approaches have undergone intensive and close scrutiny as potential approaches to treat and kill cancer (signaling pathways, multidrug resistance, cell cycle checkpoints, anti-angiogenesis, etc.), other approaches have focused on blocking the ability of a cancer cell to recognize and repair the damaged DNA that primarily results from the front-line cancer treatments; chemotherapy and radiation.

This comprehensive and timely reference focuses on the translational and clinical use of DNA repair as a target area for the development of diagnostic biomarkers and the enhancement of cancer treatment.

- Saves academic, medical, and pharma researchers time in quickly accessing the very latest details on DNA repair and cancer therapy, as opposed to searching through thousands of journal articles
- Provides a common language for cancer researchers, oncologists, and radiation oncologists to discuss their understanding of new molecular pathways, clinical targets, and anti-cancer drug development
- Provides content for researchers and research clinicians to understand the importance of the breakthroughs that are contributing to advances in disease-specific research

1. Introduction and Overview of Current Targets: Bench to Clinic

  Mark R. Kelley

2. MGMT a Critical DNA Repair Gene Target for Chemotherapy Resistance

  Stanton L. Gerson and Lili Liu

3. Blockade of Base Excision Repair: Inhibitionof Small Lesions Results in Big Consequences to Cancer Cells

  Melissa Fishel and Carlo Vascotto

4. PARP Inhibitors
Scientific Rationale and Clinical Development for Cancer

  Ruth Plummer, Nicola J. Curtin and Yvette Drew

5. Inhibiting Selective DNA Polymerases for Therapeutic Intervention

  Anthony J. Berdis

6. Targeting the Nucleotide Excision Repair Pathway for Therapeutic Applications

  John Turchi and Stephan M. Patrick

7. Homologous Recombination and ATM/ATR Targets

  Henning Willers, Lee Zou and Heike N. Pfaffle

8. DNA Double Strand Break Repair by Nonhomologous End Joining and its Clinical Relevance

  Michael Weinfeld and Susan Lees-Miller

9. Defective MMR-c-Abl-p73-GADD45alpha Expression in Cancer Chemoresistance

  David Boothman and Long Shan Li

10. DNA Repair Signaling Targets

  Susan Ashwell

11. Redox Regulation of DNA Repair and Therapeutic

  Millie M. Georgiadis

12. Personalized Cancer Medicine: DNA Repair Alterations is a Promising Predictive Marker in Cancer

  Srinivasan Madhusudan

13. The Role of DNA Damage and Repair in Neurotoxicity Caused by Cancer Therapies

  Michael R. Vasko

14. Future Directions

  Mark R. Kelley

Kelley, Mark R.
Mark R. Kelley, PhD is currently the Betty and Earl Herr Chair in Pediatric Oncology Research, Associate Director for the Herman B Wells Center for Pediatric Research, and the Associate Director of Basic Science Research at the IU Simon Cancer Center. Dr. Kelley's laboratory studies DNA base excision repair in normal and tumor cells, including the study of DNA repair genes in cognitive dysfunction and peripheral neuropathy. He holds 10 patents related to the use of DNA repair targets for cancer therapy and serves on the consulting and scientific boards of several companies. Thus far Dr. Kelley's research resulted in over 160 articles published in peer reviewed journals along with numerous reviews and book chapters.

Customers who bought this item also bought

• Personalized Medicine - Scientific and Commercial Aspects
• Therapeutic Cancer Vaccines Market to 2019 - Pipeline Indicates Safer Treatments and Extended Patient Survival, though High Prices May Limit Uptake
• Antibody Drug Target Atlas in Oncology
• Gastric Cancer (Event Driven)
• Non-Small-Cell Lung Cancer (Event Driven)
• DNA Vaccines
• Pain Therapeutics - Drugs, Markets and Companies
• Vaccines in Clinical trials: Cancer
• Current Challenges in Personalized Cancer Medicine, Vol 65
• Preclinical Cancer Therapeutics 2007: Decoding Next Generation Drug Targets for Market Success